The percentage ratios of CD163+ and CD206+ macrophages to CD68+ macrophages in CML-CP, CML-AP, and CML-BP were significantly higher than those in control group, respectively (Figures 5(a) and 5(b)). This evidence concerns the gene CD163 and chronic myelogenous leukemia, BCR-ABL1 positive.